Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-Positive Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma|Stage IB Breast Cancer AJCC v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7
Interventions: DRUG: Aromatase Inhibition Therapy|DRUG: Carboplatin|OTHER: Cytology Specimen Collection Procedure|DRUG: Docetaxel|DRUG: Goserelin Acetate|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pertuzumab|OTHER: Quality-of-Life Assessment|PROCEDURE: Therapeutic Conventional Surgery|BIOLOGICAL: Trastuzumab|RADIATION: Whole Breast Irradiation
Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology